Evangelia Razis MEDICAL ONCOLOGY Director 3rd Oncology Department, Director Contemporary Oncology Team

• American Society of Clinical Oncology (ASCO).
• American Association for Cancer Research (AACR).
• Society for Neuro-Oncology (SNO).
• National Cancer Institute (NCI) Investigator.
• European Society of Medical Oncology (ESMO).
• European Association of Neuro-Oncology (EANO).
• European Society of Mastology (EUSOMA).
• European Organization for Research and Treatment of Cancer (EORTC) Brain Tumor Group.
• European Organization for Research and Treatment of Cancer (EORTC) Breast Cancer Group.
• European Organization for Research and Treatment of Cancer (EORTC) Brain Tumor Group Quality Assurance Committee.
• Mediterranean Multidisciplinary Oncology Forum (MMOF).
• Hellenic Society of Medical Oncology (HeSMO).
• Hellenic Cooperative Oncology Group (HeCOG).
• Medical Union of Hygeia Hospital.
• Greek Medical Association.
• Athens Medical Association (Member number: 037015).
• Greek Society of Senology.
• Greek American Medical Association.
• Hellenic NeuroOncology Group Group (HeNOG).
• Hellenic Society of Head and Neck Oncology (HeSHNO).

Journal Editing

• Forum of Clinical Oncology (FCO).
• World Journal of Clinical Oncology (WJCO).
• Cancer Treatment Reviews (CTR, Occ Reviewer of papers).
• Mediterranean Oncology Journal (MOJ) – Central Nervous System Team.

Other Boards

• Member of the Early Breast Cancer Trialists’ Collaborative Group (EBCTCG), as a representative of Greece in the “ATLAS” (Adjuvant Tamoxifen Longer Against Starter) study, with an active presence in the meetings of 09/2005, 09/2010 and 09/2012.
• HeCOG representative in the Breast International Group (BIG).
• Reviewer of the National Cancer Control Plans (NCCP) of the Union for International Cancer Control (UICC) and the World Health Organization (WHO).
• Chairperson for HeCOG working party on CNS tumors.
• Has served as Director and Assistant Director of Hygeia Hospital Pharmacy Committee.

• Mental Health Worker – Adolescent Psychiatric Unit, Northwestern Memorial Hospital, 1984 – 1986.
• Internal Medicine Intern and Resident – Beth Israel Medical Center July 1987- June 1990.
• Oncology Fellow – Westchester County Medical Center/New York Medical College July 1990 – July 1993.
• Instructor New York Medical College, July 1993 – December 1993.
• Oncology Attending – Hygeia Hospital, January 1994 – December 1997.
• Associate Director – 1st Department of Medical Oncology, Hygeia Hospital, January 1998 – August 2011.
• Director, 3rd Department of Medical Oncology, Hygeia Hospital, September 2011 – to date.
• Founding member of the Contemporary Oncology Team (COT).

Teaching Experience

• Taught in many teaching seminars for oncology students and oncologists.
• Supervised the Masters Theses of two medical students.
• Regularly teaches:
  • Graduate students who attend the HYGEIA Hospital quarterly postgraduate course.
  • Dentist graduate and undergraduate students at the University of Athens School of Dentistry.
  • Nursing Seminars at HYGEIA Hospital.
  • Oncology trainees in courses organized by the Greek Academy of Oncology and the European School of Oncology.

Charity Work

Evangelia Razis has travelled extensively in many countries of Africa, Asia and South/Central America. She has worked voluntarily in the Sudan, giving lectures to women on breast and cervical cancer awareness and prevention and to the staff of the Radiotherapy Institute of Khartum (RIK), in Sri Lanka, in the Honduras, in Zimbabwe, in Rwanda and in Kefalonia, Greece.

Quality Assurance

Dr Razis led the Contemporary Oncology Team (COT) through the process of ASCO’s Quality in Oncology Practice Initiative (QOPI) participation and certification (QCP), and COT was the first practice outside the USA to achieve this certification. Additionally, she is president of the Quality Assurance Committee of the European Organization for Research and Treatment of Cancer (EORTC) Brain Tumor Group, and a member of the ASCO QOPI Steering Group.

• E.Razis. Chemotherapy for malignant gliomas in adults: ”Recent Advances in Treatment of Cerebral Gliomas”,2002. Ed, M.Torrens, E.Razis, H.Strongylos pp 107- 136. 
• E.Razis, Monoclonal Antibodies and other biological agents for Breast Cancer “Modern Mastology” 2007. Ed L. Mouzaka, A. Mandrekas, V. Barbounis. Pp953-960.
• E.Razis and G. Fountzilas. Trastuzumab Resistance. 2010, In: Aggressive Breast Cancer, Ed: Regina H. DeFrina. pp. 187-197, Nova Science Publishers, Inc.

1. C.Liakou, J.Koh, A.Tsimpidakis, K.Rios, H.Paskalis, A.Pipilis, T.Georgiadis, E.Razis. A tongue lesion as a sign of a systemic disease. Case Rep Med. 2016;2016:6723575. Epub 2016 Mar 22.
2. S.Lakis, S.Dimoudis, V.Kotoula, Z.Alexopoulou, I.Kostopoulos, T.Koletsa, M.Bobos, E.Timotheadou, I.Papaspirou, I.Efstratiou, G.Aravantinos, V.Karavasilis, F.Zagouri, H.Gogas, E.Razis, G.Pentheroudakis, C.Christodoulou, D.Pectasides, G.Fountzilas. Interaction between beta-catenin and EGFR expression by immunohistochemistry identifies prognostic subgroups in early high-risk triple negative breast cancer. Anticancer Res. 2016 May;36(5):2365-78.
3. G.Rigakos, A.Vakos, S.Papadopoulos, A.Vernadou, A.Tsimpidakis, D. Papachristou, E.Razis. Cancer of unknown primary ultimately diagnosed as male breast cancer: A rare case report. Mol Clin Oncol. 2016 Aug;5(2):263-266. Epub 2016 May 24.
4. P.Apostolou, M.Pertesi, V.Aleporou-Marinou, C.Dimitrakakis, C.Papadimitriou, E.Razis, C.Christodoulou, G.Fountzilas, D.Yannoukakos, I.Konstantopoulou, F.Fostira. Haplotype analysis reveals that the recurrent BRCA1 deletion of exons 23 and 24 is a Greek founder mutation Clin Genet. 2017 Mar;91(3):482-487. Epub 2016 Aug 22.
5. V.Kotoula; S.Lakis; I.Vlachos; E.Giannoulatou; F.Zagouri; Z.Alexopoulou; H.Gogas; D.Pectasides; G.Aravantinos; I.Efstratiou; G.Pentheroudakis; K.Papadopoulou; K.Chatzopoulos; P.Papakostas; M.Sotiropoulou; I.Nicolaou; E.Razis; A.Psyrri; P.Kosmidis; C.Papadimitriou; G.Fountzilas; Tumor infiltrating lymphocytes affect the outcome of patients with operable triple-negative breast cancer in combination with mutated amino acid classes. PLoS One. 2016 Sep 29;11(9):e0163138.
6. S.Ndarukwa, A.M.Nyakabau, A.B.Chagpar, D.Raben, N.Ndlovu, W.Kadzatsa, V.J.Eaton, P.Mafunda, E.Razis. American Society of Clinical Oncology Multidisciplinary Cancer Management Course: Connecting Lives, Cancer Care, Education, and Compassion in Zimbabwe—A Pilot for Efforts of Sustainable Benefit? JGO.2016.003673.
7. E.Fountzilas, V.Kotoula, F.Zagouri, E.Giannoulatou, G.Kouvatseas, G.Pentheroudakis, T.Koletsa, M.Bobos, K.Papadopoulou, E.Samantas, E.Demiri, S.Miliaras, C.Christodoulou, S.Chrisafi, E.Razis, F.Fostira, D.Pectasides, G.Zografos, G.Fountzilas. Disease evolution and heterogeneity in bilateral breast cancer. Am J Cancer Res. 2016 Nov 1;6(11):2611-2630. eCollection 2016.
8. G.Rigakos, C.Liakou, N.Felipe, D.Orkoulas-Razis, E.Razis. Neoplastic meningitis: clinical presentation, differential diagnosis, radiology, diagnosis. Cancer Control. Jan 2017, Vol. 24, No.1.
9. V.Kotoula, F.Fostira, K.Papadopoulou, P.Apostolou, E.Tsolaki, G.Lazaridis, K.Manoussou, F.Zagouri, D.Pectasides, I.Vlachos, I.Tikas, S.Lakis, I.Konstantopoulou G.Pentheroudakis, H.Gogas, P.Papakostas, C.Christodoulou, D.Bafaloukos; E.Razis, V.Karavasilis, C.Bamias, D.Yannoukakos, G.Fountzilas. The fate of BRCA1-related germline mutations in triple-negative breast tumors. Am J Cancer Res. 2017; 7(1): 98–114.
10. T.Strati, V.Kotoula, I.Kostopoulos, K.Manousou, C.Papadimitriou, G.Lazaridis, S.Lakis, G.Pentheroudakis, D.Pectasides, E.Pazarli, C.Christodoulou, E.Razis, K.Pavlakis, C.Magkou, S.Chrisafi, G.Aravantinos, D.Bafaloukos, P.Papakostas, H.Gogas, K.T.Kalogeras, G.Fountzilas. Prognostic subcellular Notch2, Notch3 and Jagged1 localization patterns in early triple-negative breast cancer. Anticancer Res. 2017 May; 37(5):2323-2334.
11. A.Batistatou, V.Kotoula, M.Bobos , G.Kouvatseas, F.Zagouri , E.Tsolaki, H.Gogas, A.Koutras, G.Pentheroudakis, E.Timotheadou, S.Pervana, A.Goussia, K.Petraki, M.Sotiropoulou, T.Koletsa, E.Razis, P.Kosmidis, G.Aravantinos, C.Papadimitriou, D.Pectasides, G.Fountzilas. Correlation of MYC gene and protein status with breast cancer subtypes and outcome of patients treated with anthracycline-based adjuvant chemotherapy. Pooled analysis of two Hellenic Cooperative Group phase III trials. Clin Breast Cancer. 2017 Jul 13. pii: S1526-8209(17)30138-6. doi: 10.1016/j.clbc.2017.07.004.
12. S.Levva, V.Kotoula, I.Kostopoulos, K.Manousou, C.Papadimitriou, K.Papadopoulou, S.Lakis, KKoukoulias, V.Karavasilis,  G.Pentheroudakis, E.Balassi, Z.Flora, I.G.Kaklamanos, D.Pectasides, E.Razis, G.Aravantinos, P.Papakostas, D.Bafaloukos, R.Grigorios, H.Gogas, G.Fountzilas. Prognostic evaluation of epidermal growth factor receptor (EGFR) genotype and phenotype parameters in triple-negative breast cancers. Cancer Genomics Proteomics. 2017 May-Jun; 14(3):181-195.
13. G.Rigakos, A.Kyriazoglou, A.Vernadou, S.Papadopoulos, E.Skarpidi, P.Nomikos, C.Dardoufas, G.Nassioulas, G.Kouvatseas, O.Spyri, S.Labropoulos, E.Razis. Bevacizumab in high grade glioma: Is there a subgroup that benefits?  (2017) Hematol Med Oncol, Volume 2(4): 1-7.
14. C.Christodoulou, A.Kalogera-Fountzila, V.Karavasilis, G.Kouvatseas, CN.Papandreou, E.Samantas, K.Varaki, G.Papadopoulos, M.Bobos, G.Rallis, E.Razis, A.Goudopoulou, KT.Kalogeras, KN.Syrigos, G.Fountzilas. Lapatinib with whole brain radiotherapy in patients with brain metastases from breast and non-small cell lung cancer: a phase II study of the Hellenic Cooperative Oncology Group (HeCOG). J Neurooncol. 2017 Sep;134(2):443-451. doi: 10.1007/s11060-017-2548-z.
15. M.Georgakis, P.Panagopoulou, P.Papathoma, A.Tragiannidis, A.Ryzhov, S.Zivkovic-Perisic, S.Eser, L.Taraszkiewicz, M.Sekerija, T.Zagar, L.Antunes, A.Zborovskaya, J.Bastos, M.Florea, D.Coza, A.Demetriou, D.Agius, R.M Strahinja., G.Sfakianos, I.Nikas, S.Kosmidis, E.Razis, A.Pourtsidis, M.Kantzanou, N.Dessypris, E.Th.Petridou. Central nervous system tumours among adolescents and young adults (15-39 years) in Southern and Eastern Europe: Registration improvements reveal higher incidence rates compared to the US. European Journal of Cancer 86 (2017) 46e58.

CHAPTERS/COURSES:

1. CM.Ambrus, J.Halper, M.Mahatzah, E.Razis,­ JL.Ambrus: Ethics and Methodology of studies in major complications in cancer patients: Infections, thromboembolism, hypercalcemia and osteoporosis. 1^st Conference of Philosophy Methodology Ethics and Economics in Clinical Cancer Research. Kos, Greece, May 1986 by E.Razis. Medical Ethics and/or Ethical Medicine. Elsevier, Paris 1989, p 99-105.
2. JL.Ambrus, D.Razis, TJ.Bardos, S.Stadle, J.Halpern, E.­Razis,­ H.Gustpar, E.Klein, M.Mahatzah, S.Sayid: Methodology and Ethics of new types of cancer therapy: Adoptive immunotherapy, differentiation inducing agents, antimetastatic agents, lymphokine releasers, radiation potentiators and protectors.  1^st Conference of Philosophy Kos, Greece, May 1986 by E.Razis ­Published­ in Medical Ethics and/or Ethical Medicine. Elsevier, Paris 1989, p. 88-98.
3. E.Razis.­ The role of high-dose therapy in breast cancer. “MODERN MASTOLOGY” :1996  Ed  L. Mouzaka  pp  681-687.
4. E.Razis. ESO postgraduate course on Urological cancer “Prostate cancer – Early vs late treatment”, June, 1996 Athens-Greece.
5. E.Razis. Quality of life in chemotherapy for lung cancer 2^nd International Congress on Lung Cancer. Editor George Antypas (Proceeding) Monduzzi Editore, Lung Cancer, 1996.
6. E.Razis. ESO postgraduate course on head & neck “Concurrent chemoradiotherapy in locally advanced head & neck cancer”, Sept 1996, Metsovo-Greece.
7. E.Razis. On the Knowledge of Nonexistence. THE HUMAN PREDICAMENT. An International Dialogue on the Meaning of Human Behavior. Edited by Dennis V. Razis, M.D. Prometheus Books, Amherst, New York, USA 1996.
8. E.Razis. Principles of high Dose Therapy. “Principles of cancer therapy”. Ed. G. Fountzilas and V. Barbounis Studio Press. Thess. 1997;  pp  297-322.
9. E.Razis: “Adjuvant Chemotherapy in breast cancer”, Topics in Obstetrics and Gynecology, IA:4, October-December 1997;p:408-417.
10. E.Razis. ESO postgraduate course on Melanoma and Sarcoma: “Neoadjuvant treatment for soft tissue sarcoma” Sept 1998, Athens-Greece.
11. E.Razis. ESO postgraduate course on breast cancer: “Megatherapy for Breast Cancer” Nov. 1998, Thessaloniki –Greece.
12. E.Razis. ESO postgraduate course on Urological Cancer Prognostic factors in Prostate Cancer. June 2000 , Athens-Greece.
13. E.Razis. ESO postgraduate course on Breast Cancer:”Megatherapy for Breast Cancer “Sept. 2000, Thessaloniki –Greece.
14. E.Razis, G.Fountzilas: Adjuvant Therapy for Breast Cancer: Gynecologic Oncology, 2001  Ed. Pectasides/Dimopoulos  pp 807-817.
15. E.Razis, G.Fountzilas: High dose Therapy for Breast Cancer: “Gynecologic Oncology”, 2001. Ed. Pectasides/Dimopoulos pp 887-895.
16. E.Razis, S.Lambropoulos, D.Razis. “Breast Cancer “ Chapter in Book called “Advances in Internal Medicine” 2001 Ed K. Lymperatos , E. Politakis, P. Filalithis, V. Seitanides pp 425-477.
17. E.Razis. The treatment of malignant gliomas with intratumoral chemotherapy:”Recent Advances In Treatment of Cerebral Gliomas”, 2002. Ed. M.Torrens, E.Razi, H.Strongylos, pp129-136.
18. E.Razis. Chemotherapy for malignant gliomas in adults:”Recent Advances in Treatment of Cerebral Gliomas”, 2002. Ed, M.Torrens, E.Razis, H.Strongylos pp 107- 136.
19. E.Razis, “Recent Advances in Treatment of Cerebral Gliomas”, Editors: M.Torrens, E.Razis, H.Strongylos, 2002.
20. E.Razis.1^st Postgraduate course in urologic cancer,“Carcinogenesis in bladder cancer”, Athens,Greece, October 30-31^st 2003.
21. E.Razis, Monoclonal Antibodies and other biological agents for Breast Cancer “Modern Mastology” 2007. Ed L. Mouzaka, A. Mandrekas, V. Barbounis. pp953-960.
22. E.Razis and G. Fountzilas. Trastuzumab Resistance. 2010, In: Aggressive Breast Cancer, Ed: Regina H. DeFrina. pp. 187-197, Nova Science Publishers, Inc.